Key Drivers
- High liquidity
- Zero revenue
- Negative FCF
AIAI Summary
Savara is now an event-driven, binary credit/liquidity trade: MOLBREEVI approval would unlock the Hercules facility and commercial runway, materially de-risking the stock, while a negative decision or inability to secure pre-approval financing will almost certainly force dilutive capital raises and steep repricing—investors should treat SVRA as a short-duration, approval‑dependent wager and size positions for potential total downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •Zero revenue
- •Negative FCF
SVRA has a strong, low‑leverage balance sheet with ample cash and investments but no revenue, heavy operating losses, negative free cash flow, and reliance on financing to fund R&D, making it solvent yet operationally and valuation‑risky.
Price Behavior
Key Price Behavior Insights:
- •Below last-month average
- •Downside momentum
- •Elevated volatility
SVRA is trading below its last-month moving average after a roughly 17–18% slide from $6.02 to $4.96, leaving resistance near $6.00–$6.02 and immediate support around $4.96–$5.30, which if broken would expose lower levels.
~17–18% decline from $6.02 on 2026-02-27 to $4.96 on 2026-03-20 indicating short-term volatility
Sentiment & News
Key News Insights:
- •FDA BLA momentum
- •Investor engagement
- •Institutional accumulation
Savara is advancing Molbreevi through an active FDA BLA review with an Aug 22, 2026 PDUFA date, while stepping up investor engagement and seeing notable mid‑March institutional buying.
Regulatory progress and visible institutional buying should support positive sentiment and limit downside ahead of the PDUFA, though approval remains a binary catalyst that could drive volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings